Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
BACKGROUND Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive
